PR | 7 |
ИКС | n/a |
Страниц в Google | 118000 |
Страниц в Яндексе | 0 |
Dmoz | Да |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 340448 |
Alexa Country | 200644 |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
Home | Blood Journal
n/a
n/a
UTF-8
141.19 КБ
994
8 293 симв.
7 124 симв.
Данные предоставлены сервисом semrush
Сайт | Общие фразы | PR | тИЦ | Alexa Rank | Alexa Country | |
---|---|---|---|---|---|---|
bloodjournal.org | 1876 | 7 |
80 | 32822 | 14667 | |
haematologica.org | 775 | 6 |
10 | 344010 | 291492 | |
hematology.org | 437 | 6 |
40 | 109379 | 30880 | |
leukaemia.org.au | 277 | 6 |
0 | 476093 | 20330 | |
lymphomation.org | 191 | 4 |
0 | 2110092 | Нет данных | |
bcshguidelines.com | 188 | 5 |
20 | 1168910 | Нет данных | |
pdsa.org | 182 | 5 |
0 | 1515121 | 313555 | |
mpnresearchfoundation.org | 125 | 4 |
0 | 1160907 | 387098 | |
hematologyandoncology.net | 113 | 4 |
0 | 851724 | 460526 | |
neutropenia.ca | 113 | 4 |
0 | 5875210 | Нет данных | |
mayomedicallaboratories.com | 3 | 6 |
0 | 85440 | 29904 | |
wikipedia.org | 2 | 9 |
0 | 5 | 6 | |
nih.gov | 2 | 8 |
0 | 113 | 65 | |
merckmanuals.com | 2 | 6 |
0 | 20032 | 4816 | |
hopkinsmedicine.org | 2 | 8 |
0 | 10314 | 2436 | |
buffalo.edu | 1 | 7 |
0 | 7312 | 1475 | |
bmj.com | 1 | 8 |
0 | 3590 | 2545 | |
biomedcentral.com | 1 | 8 |
0 | 3615 | 3079 | |
Еще 32 сайта после авторизации |
Данные предоставлены сервисом semrush
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
Google Analytics | Нет доступа | Нет доступа | n/a |
Данные linkpad ( 20 Апреля 2016 ) | |
Количество ссылок на сайт | 7336 |
Количество доменов, которые ссылаются на сайт | 1469 |
Количество найденных анкоров | 1851 |
Исходящие (внешние) ссылки домена | 435 |
Количество доменов, на которые ссылается сайт | 15 |
Количество исходящих анкоров | 25 |
Внешние ссылки главной страницы ( 41 ) | |
bloodjournal.org/page/topics#hubs | blood hubs™ |
bloodjournal.org/content/130/suppl_1 | 2017 |
bloodjournal.org/content/126/23 | 2015 |
bloodjournal.org/page/video-library | Video Library |
submit.bloodjournal.org/ | Submit to Blood |
bloodjournal.org/sites/default/files/additional-assets/misc/... | Classifieds |
hematology.org/ | ASH Home |
bloodadvances.org/ | Blood Advances |
facebook.com/AmericanSocietyofHematology | |
twitter.com/bloodjournal | |
youtube.com/user/ASHWebmaster | YouTube |
linkedin.com/company/american-society-of-hematology | |
bloodjournal.org/twib?ctk=TWIB | This Week in Blood A weekly snapshot of the hottest studies from Blood, the official journal of the American Society of Hematolo... |
bloodjournal.org/page/review-series/gvl?ctk=position3 | Review Series: Strategies to Improve GVL Effects Featured Review Series- March 8, 2018: 131 (10) |
bloodjournal.org/content/131/8/845 | How I treat disseminated intravascular coagulation Featured How I Treat Paper - February 22, 2018: 131 (8) |
bloodjournal.org/content/131/10/1063?ctk=position4 | The potential role of γδ T cells after allogeneic HCT for leukemia March 8, 2018: 131 (10) |
bloodjournal.org/content/131/10/1106?ctk=position5 | GPVI signaling is compromised in newly formed platelets after acute thrombocytopenia in mice March 8, 2018: 131 (10) |
bloodjournal.org/page/peer-review-week-2017 | for Your Efforts in Our Community |
hematology.org/Newsroom/Press-Releases/2017/7821.aspx | Study: Sickle Cell Anemia Treatment Does Not Increase Malaria Risk in Africa |
hematology.org/Newsroom/Press-Releases/2017/7444.aspx | Precision Therapy Enasidenib Effective in Treating Deadly Form of Leukemia |
bloodjournal.org/page/niels-borregaard | Niels Borregaard, Blood Associate Editor and colleague (1951-2017) |
hematology.org/Newsroom/Press-Releases/2016/5887.aspx | Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma |
hematology.org/Newsroom/Press-Releases/2016/5653 | AHCT Offers Safe and Effective—and Potentially Curative—Option for Patients with HIV-Associated Lymphoma |
hematology.org/Newsroom/Press-Releases/2015/4589.aspx | Study: Sirolimus is Effective, Safe for Children and Young Adults with Treatment-Resistant Autoimmune Blood Conditions |
hematology.org/Newsroom/Press-Releases/2015/4719.aspx | Study: Antibody for Severe Hemophilia A May Reduce Injections Needed to Prevent Bleeding |
hematology.org/Newsroom/Press-Releases/2015/4773.aspx | Study: Women on Blood Thinners Can Take Hormone Therapy Without Increased Risk of Blood Clots and Bleeding |
hematology.org/Newsroom/Press-Releases/2016/4912.aspx | Experts: High Drug Price Trend Has “Infected” Generics |
hematology.org/Newsroom/Press-Releases/2016/5108.aspx | Study Identifies Common Genetic Variants that Double Risk for Blood Clots in African Americans |
hematology.org/Newsroom/Press-Releases/2016/5217.aspx | Study: Analysis of Outcomes of Hemophilia Care Over 50-Year Span Reveals Progress, Ongoing Disparities |
bloodjournal.org/page/why-submit | Why Submit to Blood? |
bloodjournal.org/page/authors/copyright-information | Copyright |
bloodjournal.org/page/rights-permissions#reprints | Order Reprints |
hematology.org/research | Research |
hematology.org/education | Education |
hematology.org/advocacy | Advocacy |
hematology.org/meetings | Meetings |
hematology.org/publications | Publications |
hematology.org/store | ASH Store |
hematology.org/About/Privacy.aspx | Privacy Policy |
hematology.org/About/Terms.aspx | Terms of Service |
hematology.org/About/Contact-Us.aspx | Contact Us |
Внутренние ссылки главной страницы ( 84 ) | |
/ | Blood |
/content/current | Current Issue |
/content/early/recent | First Edition |
/collection | Collections |
/page/topics | Scientific Categories |
/page/article-collections | Article Types |
/eletters | e-Letters |
/content/by/year | All Issues |
/page/ash-annual-meeting-abstracts | Abstracts |
/content/128/22 | 2016 |
/page/about-blood | About Blood |
/page/author-center | Authors |
/page/subscriptions | Subscribers |
/page/blood-app | App |
/alerts | Alerts |
/rss | RSS |
/user/login?destination=/front%3Fsso-checked%3Dtrue%26varian... | Sign In |
/search | Advanced Search |
/content/131/10 | <img> |
/content/131/10/1045 | Posttransplant chimeric antigen receptor therapy |
/content/131/10/1063 | The potential role of γδ T cells after allogeneic HCT for leukemia |
/content/131/10/1073 | Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation |
/content/131/10/1145 | A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium |
/content/131/9/1012 | Red cell exchange transfusions lower cerebral blood flow and oxygen extraction fraction in pediatric sickle cell anemia |
/collection/free-research-articles | View All |
/content/131/7/717 | A landscape of germ line mutations in a cohort of inherited bone marrow failure patients |
/collection/plenary-papers | View All |
/content/early/2018/03/12/blood-2017-06-789321 | MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice |
/content/early/2018/03/08/blood-2017-11-737411 | Hepcidin agonists as therapeutic tools |
/content/early/2018/03/08/blood-2017-10-811505 | Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus |
/content/early/2018/03/08/blood-2017-05-743187 | Cancer and Platelet Crosstalk: Opportunities and challenges for aspirin and other anti-platelet agents |
/content/early/2018/03/08/blood-2017-09-808063 | Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma |
/content/early/2018/03/08/blood-2017-10-810622 | Two novel epigenetic pathways regulate NFE2 overexpression in myeloproliferative neoplasms |
/content/early/2018/03/07/blood-2017-12-822817 | High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma |
/content/early/2018/03/07/blood-2017-11-742577 | The MYC Oncogene is a Global Regulator of the Immune Response |
/content/early/2018/03/02/blood-2017-11-784108 | Coagulopathy induced by traumatic brain injury: systemic manifestation of a localized injury |
/content/early/2018/03/02/blood-2017-12-821009 | Five-Year Outcomes for Frontline Brentuximab Vedotin with CHP for CD30 Expressing Peripheral T-Cell Lymphomas |
/content/early/2018/03/02/blood-2017-09-772632 | Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies |
/content/early/2018/03/02/blood-2017-10-772665 | Early-stage classical Hodgkin lymphoma |
/content/early/2018/03/02/blood-2017-09-772640 | Optimizing therapy in advanced stage Hodgkin lymphoma |
/content/early/2018/03/02/blood-2018-02-824045 | Introduction to a review series on Hodgkin Lymphoma: Change is here |
/content/early/2018/03/02/blood-2017-09-772681 | Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients |
/content/early/2018/03/02/blood-2017-09-772673 | Transplant strategies in relapsed/refractory Hodgkin lymphoma |
/content/early/2018/03/02/blood-2017-11-814681 | Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium |
/content/early/2018/03/01/blood-2017-10-811752 | BTKCys481Ser drives ibrutinib resistance via ERK1/2, and protects BTKWild-Type MYD88 mutated cells by a paracrine mechanism |
/content/early/2018/02/27/blood-2017-09-805689 | Antiphospholipid Antibodies and Recurrent Thrombosis after a First Unprovoked Venous Thromboembolism |
/content/early/2018/02/27/blood-2018-01-826495 | Risk of hepatitis B virus reactivation in patients treated with ibrutinib |
/content/131/10/1148 | The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia |
/collection/clinical-trials-and-observations | View All |
/page/review-series/gvl | Strategies to Improve GVL Effects |
/page/review-series/aging | Hematologic Disease at Older Age |
/page/review-series/ta | Therapeutic Antibodies |
/page/review-series/ph | Precision Hematology |
/page/review-series/cpd | Clinical Platelet Disorders |
/page/review-series/tfhhd | Transcription Factors in Hematopoiesis and Hematologic Disease |
/page/review-series/lsc | Leukemic Stem Cells |
/page/review-series/tcell_m | T-Cell Malignancies |
/page/review-series/mn | Myeloproliferative Neoplasms |
/page/review-series/gvhd | Chronic GVHD: from Pathogenic B-cell Receptor Signaling to Novel Therapeutic Targets |
/page/review-series/cbim | Advances in Cell-Based Immune Therapeutics in Hematology |
/page/review-series/gen | Genome Editing in Hematology |
/page/review-series/who | Updated WHO Classification of Hematological Malignancies |
/page/review-series/ibcl | The Paradox of Indolent B-cell Lymphoma |
/page/review-series/mega | Megakaryocytes to Platelets in Health and Disease |
/twib | <img> |
/panels_ajax_tab/jnl_bloodjournal_most_cited/none/1 nofollow | - |
/front/tab-most-read | Most Read |
/panels_ajax_tab/jnl_bloodjournal_most_read/none/1 nofollow | - |
/front/tab-eletters | e-Letters |
/panels_ajax_tab/jnl_bloodjournal_e_letters/none/1 nofollow | - |
/content/127/20/2391 | The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia |
/content/125/16/2497 | Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib |
/content/127/20/2375 | The 2016 revision of the World Health Organization classification of lymphoid neoplasms |
/content/126/1/9 | Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes |
/content/129/4/424 | Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel |
/articles/most-cited | View all Most Cited |
/page/video-library | Video Library |
/page/about-blood/blood-newsroom | Newsroom |
/page/public-access | Public Access |
/page/rights-permissions | Permissions |
/page/contact-us | Contact Us |
/page/subscriptions/librarians | Institutions/Librarians |
/page/advertising-blood | Advertising in Blood |
/page/subscriptions/site-license | Terms and Conditions |
Британия - Ливерпуль - 213.219.33.18
Telecitygroup International Limited
Telecitygroup International Limited
HTTP/1.1 200 OK
Date: Tue, 13 Mar 2018 16:22:35 GMT
Content-Type: text/html; charset=utf-8
Content-Length: 144577
Connection: keep-alive
Set-Cookie: __cfduid=ddc60761b39a881a0514074846b96bd2d1520958155; expires=Wed, 13-Mar-19 16:22:35 GMT; path=/; domain=.bloodjournal.org; HttpOnly
Accept-Ranges: bytes
Age: 0
Cache-Control: public, max-age=900, must-revalidate, proxy-revalidate, pre-check=0, post-check=0
Cf-Railgun: 8975898e0e 0.74 0.150867 0030 e6be
Content-Language: en
Etag: "1520957479-0"
Expires: Sun, 19 Nov 1978 05:00:00 GMT
Last-Modified: Tue, 13 Mar 2018 16:11:19 GMT
Pragma: no-cache
Vary: Cookie,Accept-Encoding
Via: 1.1 varnish
X-Content-Type-Options: nosniff
X-Drupal-Cache: HIT
X-Frame-Options: SAMEORIGIN
X-Generator: Drupal 7 (http://drupal.org)
X-Highwire-Sitecode: bloodjournal
X-Highwire-Smart-Code: bloodjournal_production
X-Varnish: 1595811419
X-Varnish-Cache:
X-Varnish-Ttl:
Server: cloudflare
CF-RAY: 3fafd71565fe9fc0-IAD
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"